A gene therapy from Regeneron, a pancreatic cancer medicine from Revolution Medicines and a porphyria drug from Disc Medicine ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

However, if pharma manufacturers aren’t using RWD in a strategic way, they’ll miss out on its full potential. And with that, ...

Living with an autoimmune disease often means navigating a lifelong, complex condition. A recent study estimates that ...

Study results published in The New England Journal of Medicine show the therapy significantly improved hearing in nearly a ...

Results presented at the European Society for Medical Oncology meeting could help separate Roche’s medicine from similar ...

Backed by GV and Arch Venture Partners, Pelage Pharmaceuticals is advancing a first-of-its-kind topical gel designed to ...

Excellergy is developing medicines that combat allergic responses in three different ways, a multipronged effect the company ...

The German biotech banked one of the larger funding rounds this year to support an ovarian and non-small cell lung cancer ...

Some Wall Street analysts have questioned orforglipron’s sales outlook in obesity, but see great potential in diabetes, where ...

The deal gives Novo rights to a drug it sees as having "multiple advantages" over other treatments for so-called ...

Among the largest private biotech funding rounds this year, the financing will support global trials of an obesity shot that ...